Binocular and Monocular Distance-Corrected Visual Performance and Defocus Characteristics of Clareon Truplus Intraocular Lens (IOL) (BMVDI)

May 21, 2026 updated by: Ganesha Kandavel, Colvard Kandavel Eye Center

BMVDI Study: Binocular and Monocular Distance-Corrected Visual Performance and Defocus Characteristics of Clareon Truplus IOL

This study aims to generate data that characterizes visual outcomes, including the binocular distance-corrected intermediate visual acuity (DCIVA) at 66cm or defocus behavior, of the Clareon TruPlus modified monofocal intraocular lens (IOL).

Clareon TruPlus IOL is designed to provide an extended range of vision compared to the parent monofocal IOL. Clareon TruPlus IOL delivers excellent intermediate vision without compromising distance vision including the quality of vision with low incidence of visual disturbances in normal cataract patients.

Binocular distance-corrected intermediate visual acuity at 66cm will be assessed at a pre-specified postoperative interval 12 weeks after second eye surgery. This study hypothesizes that Clareon TruPlus IOL delivers good binocular DCIVA at 66cm 12 weeks after second eye surgery.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Encino, California, United States, 91316
        • Colvard-Kandavel Eye Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Colvard-Kandavel Eye Center patients with bilateral cataracts

Description

Inclusion Criteria:

  • Able and willing to understand and sign informed consent.
  • Able and willing to complete all required study visits.
  • Diagnosed with age-related cataracts in both eyes (OU)
  • Bilateral age-related cataract scheduled for phacoemulsification in both eyes by a single surgeon.
  • Surgeon predicts postoperative best corrected distance visual acuity (BCDVA) of ≥ 20/25 or better with Manifest Refractive Spherical Equivalent (MRSE) ±0.50 D of plano and in each eye post-operatively.
  • Clear intraocular media aside from cataract.
  • Will receive TruPlus bilaterally
  • Postoperative residual astigmatism ≤ 0.75 D in both eyes.
  • Refractive target: Emmetropia OU
  • Patient groups agreeing to either Femtosecond Laser Assisted Cataract Surgery (FLACS) or Standard phaco

Exclusion Criteria:

  • Ocular comorbidities affecting visual outcomes, including but not limited to:
  • Macular disease (e.g., Age-Related Macular Degeneration [AMD], Diabetic Macular Edema [DME], Epiretinal Membrane [ERM]).
  • Active ocular inflammation.
  • Any investigator-determined condition likely to confound postoperative visual performance.
  • Strabismus with or without amblyopia in either eye.
  • Prior anterior or posterior segment surgery, including corneal refractive procedures.
  • History of retinal detachment.
  • Degenerative retinal or visual disorders deemed clinically significant by the investigator.
  • Diagnosed glaucoma (of any stage, if deemed vision-impacting by investigator).
  • Systemic conditions that could affect healing or study outcomes (e.g., immunocompromised, connective tissue disease, clinically significant atopy, diabetes).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Binocular distance-corrected intermediate visual acuity (DCIVA) and Logarithm of the Minimum Angle of Resolution (logMAR) at 66cm at 12 weeks after second eye surgery
Time Frame: Baseline and 12 weeks after second eye surgery
Baseline and 12 weeks after second eye surgery

Secondary Outcome Measures

Outcome Measure
Time Frame
Monocular DCIVA at 66cm
Time Frame: Baseline and 12 weeks after second eye surgery
Baseline and 12 weeks after second eye surgery
Monocular and Binocular distance corrected Defocus curve (at 3m) from +1.00D to -2.50D
Time Frame: Baseline and 12 weeks after second eye surgery
Baseline and 12 weeks after second eye surgery
Monocular and Binocular Best Distance Corrected Visual Acuity (BDCVA)
Time Frame: Baseline and 12 weeks after second eye surgery
Baseline and 12 weeks after second eye surgery
Binocular Uncorrected Distance Visual Acuity (UDVA) at 4m, Uncorrected Intermediate Visual Acuity (UCIVA) at 66cm
Time Frame: Baseline and 12 weeks after second eye surgery
Baseline and 12 weeks after second eye surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Colvard Kandavel Eye Center

Investigators

  • Principal Investigator: Ganesha R Kandavel, MD, Coilvard-Kandavel Eye Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

May 11, 2026

First Submitted That Met QC Criteria

May 11, 2026

First Posted (Actual)

May 15, 2026

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BMVDI-102745323

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract

Clinical Trials on Clareon TruPlus IOL

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe